Sofie subsidiary iTheranostics has inked an agreement with Novartis to collaborate on the development of therapeutic fibroblast activation protein (FAP) drugs.
iTheranostics' library of these drugs has been licensed from the University of Heidelberg in Germany. Under the terms of the deal, Novartis will develop therapeutic uses of this family of compounds, while iTheranostics will be responsible for commercializing the developed imaging agents. Sofie may facilitate clinical supply and will be responsible for the commercialization of FAP-targeted PET imaging tracers around the world, it said.
